We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

Facebook
LinkedIn

Search for:

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Search for:

News
Newsletter
- Featured Articles
- Newsletter Subscribe
Events
Media

Nasdaq News Release

1 July 2016

Nasdaq has issued a News Release to welcome AroCell to First North
Please follow the enclosed link for the official document:
20160630_AroCell_FINAL

Categories

News
Press Releases

Latest posts

AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium
22 September 2017
Webinar announcement and invitation
20 September 2017
New application for AroCell TK 210 ELISA opens new opportunities for drug development research
18 September 2017
AroCell AB Interim Report, Q2 2017
24 August 2017
TK 210 ELISA appears in latest issue Genetic Engineering & Biotechnology News
7 August 2017

Archive

2017
- AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium
  22 September 2017
- Webinar announcement and invitation
  20 September 2017
- New application for AroCell TK 210 ELISA opens new opportunities for drug development research
  18 September 2017
- AroCell AB Interim Report, Q2 2017
  24 August 2017
- TK 210 ELISA appears in latest issue Genetic Engineering & Biotechnology News
  7 August 2017
- Beslut vid årsstämman i AroCell AB (publ) 2017
  18 May 2017
- AroCell AB (publ) Interim report for period 1 January – 31 March 2017
  11 May 2017
- AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia
  19 April 2017
- KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)
  13 April 2017
- AroCell TK 210 ELISA Webinar Recording is now available!
  28 March 2017
- AroCell AB (publ) Year-End Report
  16 February 2017
- AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)
  24 January 2017
- Nomination committee appointed for Annual General Meeting 2017
  19 January 2017
2016
- Announcement – AroCell AB PR and Marketing Communications Manager
  19 December 2016
- Interim report January – September 2016
  17 November 2016
- Ann Hammarstrand appointed as new CFO to AroCell
  3 November 2016
- AroCell signs distribution agreement with Eagle Biosciences in the United States
  6 October 2016
- New TK 210 ELISA product presentation
  2 October 2016
- Oral presentation today of TK 210 ELISA abstract at ISOBM, Chicago
  4 September 2016
- Interim report January – June 2016
  25 August 2016
- Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.
  12 August 2016
- Nasdaq News Release
  1 July 2016
- AroCell is approved for listing on the Nasdaq First North and publishes Corporate description
  28 June 2016
- AroCell applying for listing on the Nasdaq First North exchange
  21 June 2016
- Christine Tadgell new board member in AroCell
  23 May 2016
- CEO Jan Stålemark’s presentation at the AGM 2016
  19 May 2016
- Report from the Annual General Meeting of AroCell
  19 May 2016
- AroCell Newsletter for May is now available
  11 May 2016
- Interim report January – March 2016
  10 May 2016
- Leading profile in biomarkers joins the AroCell management team
  2 May 2016
- New patent strengthens the AroCell patent portfolio
  28 April 2016
- Annual Report 2015
  27 April 2016
- New clinical study with promising results for the TK 210 ELISA test from AroCell
  18 April 2016
- Kallelse till årsstämma i AroCell AB (publ)
  18 April 2016
- Final call for trading with BTA
  8 January 2016
2015
- Nomination committee appointed for Annual General Meeting 2016
  17 December 2015
- Oversubscription of preferential rights issue
  8 December 2015
- Sign up for our Newsletter!
  8 December 2015
- Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1
  2 December 2015
- Interview with CEO Jan Stålemark for Analysguiden, November 2015
  30 November 2015
- Presentation from Stora Aktiedagen Göteborg, November 23
  30 November 2015
- AroCell announces prospectus, teaser and application form
  17 November 2015
- Progress for development of prostate treatment, results from STHLM3 presented today
  10 November 2015
- AroCell announces interim report three will be brought forward
  6 November 2015
- Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK
  6 November 2015
- Continued expansion to AroCell organization
  23 October 2015
- AroCell presents a robust TK1 blood-test at an international biomarker meeting
  19 October 2015
- Clarification regarding press release about CE marking
  2 October 2015
- AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA
  1 October 2015
- AroCell announces achievement of critical milestone: successful phase 1 review of TK 210 ELISA production process.
  17 August 2015
- AroCell recognized by EU Commission and Horizon 2020 Program Committee
  13 August 2015
- AroCell strengthens the organization
  5 June 2015
- Report from the annual general meeting of AroCell
  3 June 2015
- Notice of annual general meeting of AroCell AB (publ)
  6 May 2015
- Schedule revision providing for CE-mark during third quarter 2015
  12 February 2015
- Revised schedule means CE-marking during the third quarter of 2015
  12 February 2015
2014
- New clinical study with promising results
  29 October 2014

Newsletter

Product
Research & References
News & Media
About AroCell
Investors
Contact
To Order

Facebook
LinkedIn

AroCell AB Uppsala Business Park
Virdings allé 32 B SE-754 50 Uppsala Sweden

info@arocell.com
+46 (0)706 92 62 06

© 2017 AroCell AB. All rights reserved.

All of the information appearing on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not either constitute medical and/or other professional advice.
TK 210 ELISA is CE-marked and registered by the Swedish Medical Products Agency.